LaNova Medicines, founded in September 2019 and based in Shanghai, is a privately held clinical-stage biotech developing ADCs, bispecifics and monoclonal antibodies. Its pipeline includes six clinical-stage assets and more than ten preclinical programs, led by LM-302 (anti‑CLDN18.2 ADC), LM-108 (anti‑CCR8 mAb) and LM-299 (anti‑PD‑1/VEGF bispecific). LM-299 has entered a Phase I trial in China and LaNova expects to submit a U.S. IND in H2 2024. LM-302 is in a Phase III registrational trial in China with a planned U.S. Phase II start in H2 2025; LM-108 is in Phase II in China with planned U.S. Phase II and China Phase III milestones in H2 2024. The company emphasizes differentiated platform technologies for challenging targets and intends to advance its late-stage clinical programs toward registrational milestones. Recent financing proceeds will be used primarily to advance clinical development across the pipeline. LaNova Medicines completed a Series A financing in November 2020. The financing was led by Qiming Venture Partners, with China Renaissance acting as financial adviser. The announcement names additional investors including TF Capital, Yingke PE, Hony Capital, Biotrack Capital and YF Capital, among others. The article does not provide details on the company's product offerings, future plans, or operating metrics. The size of the Series A was not disclosed in the announcement. The announcement highlights Qiming Venture Partners' reputation, describing it as a top-tier VC firm with global recognition.

Total raised

$42M

Funding rounds

2

Latest round

Series C

Latest activity

Oct 2024